Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSPO Validation in SPMS
NCT03850301Recruiting
- Sponsor
- Imperial College London
- Start
- Jan 2018
- Primary completion
- Jan 2025
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of emapunil and etifoxine in secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Imperial College London. Primary endpoints: Monocyte phenotype - Tissue necrosis factor-alpha at 7 days, Monocyte phenotype - Interferon-gamma at 7 days and 8 more. Started Jan 2018; status: recruiting.
02
Drugs
emapuniletifoxine
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT03850301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850301.